Continuous subcutaneous administration of teriparatide as a therapeutic option in chronic hypoparathyroidism: retrospective study in three tertiary care centers of the epi-hypo study
CSAT may be an option for patients with uncontrolled cHP. Further studies need to investigate bone consequences and better characterize the improvement of QoL among these patients.
Authors
- Amina Attia (ORCID: https://orcid.org/0009-0001-0570-749X)
- P. Kamenicky
- Luigi Maione (ORCID: https://orcid.org/0000-0001-8526-8046)
- C. Ghander
- M. Brière
- Pascal Houillier
- Anne-Lise Lecoq
- Camille Buffet
- Jean-Philippe Bertocchio
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Pitié-Salpêtrière Hospital (FR)
- Bicêtre Hospital (FR)
- Groupe de recherche clinique – Tumeurs Thyroïdiennes
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1093/ejendo/lvaf257
- Primary Topic
- Thyroid and Parathyroid Surgery
- Type
- article
- Field-Weighted Citation Impact
- 0.00